Home » Stocks » CTMX

CytomX Therapeutics, Inc. (CTMX)

Stock Price: $5.55 USD -0.08 (-1.42%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $5.52 -0.03 (-0.54%) Jul 23, 7:39 PM
Market Cap 360.81M
Revenue (ttm) 66.74M
Net Income (ttm) -60.64M
Shares Out 60.97M
EPS (ttm) -1.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $5.55
Previous Close $5.63
Change ($) -0.08
Change (%) -1.42%
Day's Open 5.69
Day's Range 5.52 - 5.74
Day's Volume 462,382
52-Week Range 5.52 - 10.05

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CytomX Therapeutics (CTMX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...

1 week ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigat...

1 month ago - GlobeNewsWire

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 10.34% and -21.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigat...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investig...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investi...

3 months ago - GlobeNewsWire

With the trading day about halfway over, the broad markets were pushing lower. The Dow Jones industrial average and S&P 500 were only down slightly to start the week, while the Nasdaq faced the worst of...

Other stocks mentioned: CODX, DOCU, CREE, DHT, DOW, MDLA, NMR ...
3 months ago - 24/7 Wall Street

SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investi...

4 months ago - GlobeNewsWire

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 months ago - Zacks Investment Research

CytomX Therapeutics (CTMX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

4 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investig...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives w...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives w...

5 months ago - GlobeNewsWire

Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm entered an 8.9% stake in CytomX Therapeutics Inc. (NASDAQ:CTMX).

5 months ago - GuruFocus

All four biotechs announced the pricing of stock offerings.

Other stocks mentioned: EDIT, INO
6 months ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives w...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives w...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...

7 months ago - GlobeNewsWire

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AXLA, KLDO, MGTA
7 months ago - 24/7 Wall Street

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...

8 months ago - GlobeNewsWire

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 11.11% and 1.95%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT

8 months ago - GlobeNewsWire

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

-Teleconference Scheduled for November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT- -Teleconference Scheduled for November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT-

8 months ago - GlobeNewsWire

Marcia P. Belvin, Ph.D., Promoted to Senior Vice President, Head of Research

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi...

10 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of invest...

10 months ago - GlobeNewsWire

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi...

11 months ago - GlobeNewsWire

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

NEW YORK, July 20, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. between May 17, 2018, and May 13, 2020, inclu...

1 year ago - PRNewsWire

New York, New York--(Newsfile Corp. - July 20, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against CytomX Therapeutics, Inc.

1 year ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - July 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics...

1 year ago - Newsfile Corp

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AXLA, KLDO, MGTA
1 year ago - 24/7 Wall Street

New York, New York--(Newsfile Corp. - July 17, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc.

1 year ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - July 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics...

1 year ago - Newsfile Corp

New York, New York--(Newsfile Corp. - July 16, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytomX Therapeutics, Inc.

1 year ago - Newsfile Corp

New York, New York--(Newsfile Corp. - July 16, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cyto...

1 year ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - July 16, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics...

1 year ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - July 15, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics...

1 year ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against CytomX Therapeutics, Inc. ("CytomX" or "the Company") (Nasdaq: CTMX) an...

1 year ago - Business Wire

Los Angeles, California--(Newsfile Corp. - July 14, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics...

1 year ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - July 13, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics...

1 year ago - Newsfile Corp

NEW YORK, July 10, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) between May 17, 2018, and May ...

1 year ago - PRNewsWire

NEW YORK, July 7, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) between May 17, 2018, and May 1...

1 year ago - PRNewsWire

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gas... [Read more...]

Industry
Biotechnology
IPO Date
Oct 8, 2015
CEO
Sean McCarthy
Employees
144
Stock Exchange
NASDAQ
Ticker Symbol
CTMX
Full Company Profile

Financial Performance

In 2020, CTMX's revenue was $100.36 million, an increase of 74.58% compared to the previous year's $57.49 million. Losses were -$32.89 million, -67.83% less than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for CTMX stock is "Buy." The 12-month stock price forecast is 12.94, which is an increase of 133.15% from the latest price.

Price Target
$12.94
(133.15% upside)
Analyst Consensus: Buy